- Amphastar Pharmaceuticals (AMPH) said that the U.S. Food and Drug Administration has approved the company’s abbreviated new drug application for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen.
- The FDA determined that Amphastar’s teriparatide is bioequivalent and therapeutically
